Evidence map›Paper›PMID 24840607›Full record

ReviewAmerican journal of hematology2014

The glomerulopathy of sickle cell disease.

Kenneth I Ataga, Vimal K Derebail, David R Archer

2 registry-linked trialsOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 85 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 4 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03277547 active not recruitingnot on this mapstarted 2017, after this paper: background citation

The Association of Biomarkers of Endothelial Function With Prospective Changes in Kidney Function in Sickle Cell Anemia

TypeobservationalSponsorKenneth Ataga MDRan2017 to 2025Enrolled300ConditionsSickle Cell Disease, Kidney Failure, Chronic
NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 4 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Interventions for chronic kidney disease in people with sickle cell disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Interventions for chronic kidney disease in people with sickle cell disease.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kenneth I AtagaDivision of Hematology/Oncology, University of North Carolina, Chapel Hill, NC.
Vimal K Derebail
David R Archer
University of North Carolina at Chapel Hill · USEmory University · US

Funding

Endothelial Dysfunction in the Pathogenesis of Sickle Cell NephropathyR01HL111659 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARCHER, DAVID R, ATAGA, KENNETH I · 2012 to 2016
$2.3M
NHLBI NIH HHS R01 HL111659
6 · The paper itself

Abstract

Sickle cell disease (SCD) produces many structural and functional abnormalities in the kidney, including glomerular abnormalities. Albuminuria is the most common manifestation of glomerular damage, with a prevalence between 26 and 68% in adult patients. The pathophysiology of albuminuria in SCD is likely multifactorial, with contributions from hyperfiltration, glomerular hypertension, ischemia-reperfusion injury, oxidative stress, decreased nitric oxide (NO) bioavailability, and endothelial dysfunction. Although its natural history in SCD remains inadequately defined, albuminuria is associated with increased echocardiography-derived tricuspid regurgitant jet velocity, systemic blood pressure, and hypertension, as well as history of stroke, suggesting a shared vasculopathic pathophysiology. While most patients with albuminuria are treated with angiotensin converting enzyme inhibitors/angiotensin receptor blockers, there are no published long-term data on the efficacy of these agents. With the improved patient survival following kidney transplantation, SCD patients with end-stage renal disease should be considered for this treatment modality. Given the high prevalence of albuminuria and its association with multiple SCD-related clinical complications, additional studies are needed to answer several clinically important questions in a bid to adequately elucidate its pathophysiology, natural history, and treatment.

Indexed as

AlbuminuriaAnemia, Sickle CellAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsGlomerulonephritisHumansKidney Failure, ChronicKidney TransplantationAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Identifiers

PMID24840607
PMCPMC4320776
OpenAlexW1956685882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.